Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

June
05
2024

Summer, Sun, and Skin: SRT as the Future of Non-Invasive Skin Cancer Treatments

As summer approaches, the allure of sunny days and outdoor activities beckons. However, amidst the joys of the season, it’s essential to remain vigilant about skin health, particularly in light of the rising incidence of…

May
24
2024

Ranking the 7 Best Treatments for Non-Melanoma Skin Cancer

Non-melanoma skin cancers, primarily comprising basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), represent the most common types of skin cancer. Fortunately, advancements in dermatological treatments offer various effective options for managing these conditions….

May
09
2024

Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold

Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year quarter Launched the “Fair Deal Agreement” recurring…

May
09
2024

Largest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Healthcare’s SRT-100™ to Provide Gentler Radiotherapy to Treat Tumors in Dogs and Cats

First veterinary commercial sale of the SRT-100 outside the U.S. BOCA RATON, Fla., May 09, 2024 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments…

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy